Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction

Fig. 2

Delta (final minus initial content in cholesterol) of intermediate-density lipoprotein (IDL) subfractions by lipid-lowering therapies. A The delta of IDL-A (nonatherogenic) was similar after simvastatin plus ezetimibe or rosuvastatin treatment. B The delta of IDL-B plus IDL-C (atherogenic) showed higher effectiveness with simvastin plus ezetimibe than rosuvastatin monotherapy (*P = 0.047, Mann–Whitney U test)

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X